- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
| 08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | - | Investing.com Deutsch | ||
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 71 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 166 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 149 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 19.03. | Sera Prognostics appoints Jeff Elliott to board | 1 | Investing.com | ||
| 19.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Sera Prognostics GAAP EPS of -$0.25 misses by $0.01, revenue of $0.02M | 4 | Seeking Alpha | ||
| 19.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.02. | Sera Prognostics dips 5%, prices $50M offering | 3 | Seeking Alpha | ||
| 10.02. | Sera Prognostics announces proposed public offering | 3 | Seeking Alpha | ||
| 10.02. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 102 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 07.08.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 138 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,695 | +0,89 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
| OCUGEN | 0,839 | +8,65 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,840 | +0,80 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
| COSCIENS BIOPHARMA | 3,240 | -1,82 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 9,610 | -0,52 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| VAXART | 0,358 | +1,02 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
| REDHILL BIOPHARMA | 1,900 | +2,70 % | RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency | The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected... ► Artikel lesen | |
| IBIO | 0,890 | -2,20 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,962 | -0,74 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| ALDEYRA | 2,159 | -0,46 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MANNKIND | 3,729 | -2,05 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,200 | +0,95 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 | - Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate - - The trial evaluated three doses... ► Artikel lesen | |
| TRAWS PHARMA | 1,270 | -100,00 % | Traws Pharma Stock Soars 40% On Positive Clinical Data For Oncology Asset | ||
| CARISMA THERAPEUTICS INC | 0,160 | +3,98 % | Carisma Therapeutics Inc.: Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline | Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies
Development of CT-0525... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.